Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on July 13, 2005, primarily to report the election of James L. Vincent to its Board of Directors. This appointment fills a vacancy and brings a new director to the board with a term expiring in 2006. Mr. Vincent's addition is accompanied by significant equity awards, indicating a strategic move to integrate key personnel and align incentives.
Key Highlights
- 1James L. Vincent elected to the Board of Directors on July 12, 2005.
- 2Mr. Vincent fills a vacancy on the Board and will serve as a Class II director.
- 3Mr. Vincent received a stock option award to purchase 75,000 shares of common stock at an exercise price of $7.02 per share.
- 4Mr. Vincent was granted 10,000 shares of restricted stock at a purchase price of $7.02 per share.
- 5Stock options vest over three years, subject to continued service.
- 6Restricted stock vests one week after election, contingent on continued service.
- 7Exhibits include the forms of the Nonstatutory Stock Option Agreement and Restricted Stock Agreement.
Frequently Asked Questions
James L. Vincent was elected to the Alnylam Pharmaceuticals, Inc. Board of Directors on July 12, 2005, to fill an existing vacancy. His appointment is a key event noted in this 8-K filing.
Mr. Vincent received two types of equity awards: nonstatutory stock options to purchase 75,000 shares of common stock at $7.02 per share, and a restricted stock award for 10,000 shares purchased at $7.02 per share.
The stock options vest one-third annually over three years, provided he continues to serve on the Board. The restricted stock vests in one week, contingent on his continued service as a director at that time.
The $7.02 per share price for both the stock options and restricted stock likely represents the fair market value of Alnylam's common stock on the date of grant, a common practice for such awards to new board members.